20:4-NAPE induced changes of mechanical sensitivity and DRG neurons excitability are concentration dependent and mediated via NAPE-PLD
https://ror.org/05xw0ep96grid.418925.30000 0004 0633 9419Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
Abstract
Alterations in the excitability of dorsal root ganglion (DRG) neurons are critical in the pathogenesis of acute and chronic pain. Neurotransmitter release from the terminals of DRG neurons is regulated by cannabinoid receptor 1 (CB1) and transient receptor potential vanilloid 1 (TRPV1), both activated by anandamide (AEA). In our experiments, the AEA precursor N-arachidonoylphosphatidylethanolamine (20:4-NAPE) was used to study the modulation of nociceptive DRG neurons excitability using K+-evoked Ca2+ transients. Intrathecal administration was used to evaluate in vivo effects. Application of 20:4-NAPE at lower concentrations (10 nM − 1 µM) decreased the excitability of DRG neurons, whereas the higher (10 µM) increased it. Both effects of 20:4-NAPE were blocked by the N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor LEI-401. Similarly, lower concentrations of externally applied AEA (1 nM − 10 nM) inhibited DRG neurons, whereas higher concentration (100 nM) did not change it. High AEA concentration (10 µM) evoked Ca2+ transients dependent on TRPV1 activation in separate experiments. Inhibition of the CB1 receptor by PF514273 (400 nM) prevented the 20:4-NAPE- and AEA-induced inhibition, whereas TRPV1 inhibition by SB366791 (1 µM) prevented the increased DRG neuron excitability. In behavioral tests, lower 20:4-NAPE concentration caused hyposensitivity, while higher evoked mechanical allodynia. Intrathecal LEI-401 prevented both in vivo effects of 20:4-NAPE. These results highlight anti- and pro-nociceptive effects of 20:4-NAPE mediated by CB1 and TRPV1 in concentration-dependent manner. Our study underscores the complexity of endocannabinoid signaling in pain transmission modulation and highlights 20:4-NAPE as a potential therapeutic target, offering new insights for developing analgesic strategies.
Introduction
The discovery of anandamide in 1992 (N-arachidonoylethanolamine, AEA), the first isolated endocannabinoid, a derivative of arachidonic acid synthesized in many peripheral tissues and organs as well as in central and peripheral nervous system led to early recognition of AEA as a critical mediator in many pathophysiological states including pain1–3. Even more than 30 years after the AEA identification, the mechanisms of AEA-mediated analgesia are still not fully understood. Extensive investigation, predominantly in rodent models, has brought exciting preclinical insights into AEA’s role in pathological pain conditions4,5. However, clinical trial failures of AEA-related drugs6,7 underscore the need for a deeper comprehension of AEA-induced effects, underlying mechanisms, and disparities between rodents and human physiology before advancing in clinical development. These disparities pose a major challenge for the translation of preclinical findings into effective clinical therapies, highlighting the need for more nuanced investigations into AEA’s mechanisms of action. Modulation of AEA metabolism is one of the challenges, and focusing on the AEA precursor 20:4-NAPE may be a novel approach to locally target the endocannabinoid system to elicit analgesia8,9.
Nociceptive signaling from the periphery is transmitted from primary sensory neurons (DRG neurons) to dorsal horn neurons. In the superficial spinal cord dorsal horn, there is abundant co-expression of two essential AEA targets, CB1 and TRPV1 receptors10,11. The vast majority of both these receptors are presynaptically localized on the central endings of DRG neurons, and their activation modulates excitatory neurotransmitter release from these sensory fibers. Meanwhile, the opposite regulation of glutamate release from DRG neurons by CB1 and TRPV1 receptors activation may occur at these first nociceptive synapses. Activation of G-protein coupled receptor CB1 decreases glutamate release via inhibition of high-voltage activated N- and P/Q-type Ca2+ channels and activation of inwardly rectifying potassium channels12. In comparison, the accumulation of Ca2+ ions in the central endings of DRG neurons, following activation of the Ca2+-permeable TRPV1 channels, represents the essential stimulus to trigger neurotransmitter release13–15. In particular, the application of exogenous AEA to spinal cord slices elicits a dual excitatory and inhibitory effect at these first nociceptive synapses16,17. However, peripheral inflammation altered this balance and shifted the AEA-induced responses predominantly toward neurotransmitter release inhibition17. These effects of externally applied AEA contrast with the apparent inhibitory effects of 20:4-NAPE application18,19. Together, these results suggest that the impact of AEA on nociceptive synaptic transmission may vary significantly depending on whether it is applied externally or synthesized locally from precursors by available enzymes and is further modulated under pathological conditions.
AEA is synthesized from membrane phospholipids primarily by the enzyme N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) when intracellular [Ca2+] increases during stimulation19–21. NAPE-PLD ensures the production of N-acylethanolamines (NAEs) from NAPEs or pNAPEs22. Moreover, AEA synthesis may occur through alternative anabolic Ca2+-insensitive pathways. Protein kinases (PK) A and C are implicated in this alternative AEA production in DRG neurons23,24. Subsequently, degradation of AEA into arachidonic acid and ethanolamine is rapidly ensured by fatty acid amino hydrolase (FAAH).
The objective of this work was to investigate the analgesic potential of various concentrations of 20:4-NAPE in vivo, using intrathecal administration and tactile sensitivity alteration assessment. The second objective was to study how 20:4-NAPE modulates the excitability of DRG neurons in vitro, compared to externally applied AEA in dissociated DRG cultures, with a particular focus on NAPE-PLD activity and CB1- and TRPV1-receptor-mediated mechanisms.
Materials and methods
Animals
Adult male Wistar rats (Institute of Physiology CAS, Czech Republic) were maintained at 22 ± 2 °C in light-controlled 12 h light/dark cycle conditions with free access to food and water. All experiments were approved by the local Institutional Animal Care and Use Committee and were carried out in accordance with the EU Directive 2010/63/EU for animal experiments, ARRIVE guidelines (https://arriveguidelines.org), the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals, and guidelines of the International Association for the Study of Pain.
DRG cell culture Preparation
DRG cells were isolated from adult male Wistar rats (approximately 200 g body weight) based on the previous protocol25 with modifications described in our previous work26. Briefly, rats were anesthetized deeply with Isofuran®, and intact L3-L5 DRGs (total 6 per animal) were dissected out bilateral to the spinal cord and collected in ice-cold DMEM (Invitrogen, #10566-016). The DRGs were then incubated in a pre-warmed enzyme cocktail containing 4 mg/ml Collagenase Type II (Invitrogen, #17101015) and 3 mg/ml (∼2 U/ml) Dispase II (Sigma-Aldrich, #D4693) for 45 min in a 37 °C incubator (oxygenated with 95% O2 and 5% CO2). The enzyme solution was washed out gently with fresh DMEM, and tissues were transferred to a 15 ml Falcon tube containing DMEM with 1% BSA and 1 mg/ml DNAase. DRG tissues were triturated with a glass Pasteur pipette in this solution using up and down strokes and mechanically dispersed. Digested and dispersed cells were filtered using a 40 μm Corning® cell strainer (Sigma-Aldrich, #CLS431750) to obtain cell suspension devoid of undigested tissue debris and larger diameter (non-nociceptive) cells. Suspended DRG cells were then centrifuged at 200 × g for 5 min, washed by repeating the centrifugation step, and the obtained pellet was re-suspended in approximately 500 µl growth media containing 1:1 DMEM/F-12 (Invitrogen, #31331-028), 10% of Fetal Bovine Serum (FBS, Sigma-Aldrich), and 100 U/ml penicillin-streptomycin (Gibco, Thermo Scientific). 30–40 µl of DRG cell suspension was spotted onto 10 mm glass coverslips coated with poly-D-lysine (1 mg/ml) and laminin (0.02 mg/ml) and incubated for 2 h at 37 °C. The unattached and dead cells were washed out from the coverslips by adding fresh growth media after 2 h of plating, and the attached cells were kept in the incubator overnight at 37 °C. The cells were stained and imaged the next day, 18–24 h after). All procedures except animal dissection were performed in sterile conditions in a culture hood.
Calcium imaging
Calcium imaging experiments were performed according to the established protocol27 with appropriate adjustments. Briefly, glass coverslips with attached DRG cells were incubated in artificial cerebrospinal fluid (ACSF) containing membrane permeable Ca2+ indicator dye Fura-2-acetoxymethyl ester (Fura-2 AM; Invitrogen, # F-1221) at a final concentration of 1 µM and Pluronic F-127 (Sigma-Aldrich) dissolved in DMSO at a final concentration of 0.01% for either 45 min in a 37 °C incubator or 1 h at room temperature in darkness. The ACSF solution contained 142 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose adjusted to pH 7.4 with NaOH. Fura-2 incubated cells were washed 3 × in ACSF, and fluorescence images were captured in real-time under a 20 × water immersion objective using a Leica DM LB2 microscope (Leica Microsystems, Germany). Cells were exposed to alternating 340 and 380 nm wavelengths of excitation and emissions. The emitted light images were collected at 510 nm (TILL Photonics) during image recording at a frame rate of 1 Hz. Post-hoc image analysis was performed using MetaFluor® software (Molecular Devices, USA) as a time-series experiment. The ratio of light intensity (340/380 nm) reflected changes in intracellular free Ca2+ concentration ([Ca2+]i) and was followed in ≥ 30 DRG cells simultaneously. During the experiment, cells were continually perfused with ACSF, in which all tested drugs where dissolved and applied focally to the cells under the field-of-vision using a custom gravity-driven fast perfusion system WAS-0228 attached with a fiber-glass application outlet of 0.1 mm diameter.
Experimental protocols
A high concentration of KCl (30 mM) was focally applied for 2 s repeatedly at 2 min intervals. The average amplitude of two K+-induced Ca2+ responses was calculated and set as a control value before drug treatment. Subsequently, different concentrations of 20:4-NAPE (10 nM, 100 nM, 1 µM, and 10 µM) and AEA (1 nM, 10 nM, and 100 nM) were administered for 6 min to evaluate the impact on K+-induced responses. Inhibition of K+ responses was calculated in % of control value before treatment. At the end of the experimental protocol, the TRPV1 agonist capsaicin (0.5 µM, 3 s) application was used to identify TRPV1-positive cells.
Inhibition of CB1 and TRPV1 receptors was tested using antagonists PF514273 (400 nM) and SB366791 (1 µM) pretreatment (4 min) followed by 6 min co-application with 20:4-NAPE (100 nM, 10 µM) and AEA (10 nM), respectively. The effect of the NAPE-PLD inhibitor LEI-401 (1 µM) was studied using DRG culture incubation (2 h) followed by acute application during the experimental protocol involving repetitive KCl (30 mM, 2s, 2-min interval) applications.
The effect of the high concentration of AEA (10 µM) was studied using a protocol consisting of 1st KCl (30 mM, 2 s) application followed by five consecutive applications of AEA (10 µM, 2 s, 2-min interval). When antagonists PF514273 (400 nM) and SB366791 (1 µM) were tested, the 6 min application of antagonists was used after the two short AEA applications.
Behavioral testing
Electronic von Frey test
Adult male Wistar rats (250–300 g) used in experiments were housed with a 12 h light/12 h dark cycle and in standard conditions with food and drinking water available ad libitum. Rats were placed in clear plastic cages on a grid or glass plate and left to adapt to the testing environment for at least 20 min before any stimulation. Paw withdrawal threshold (PWT) to tactile stimulation was tested manually using the electronic von Frey apparatus (IITC Life Sciences, Model 2390 Series). The PWT was tested 4 times for each hind paw with at least 5 min intervals between the trials. The average value from each hind paw was calculated and then averaged in the experimental group. All procedures were based on our established behavioral tests29–31. The baseline withdrawal threshold was acquired at the beginning of each experimental protocol before drug administration.
Design of experiments
In the first series of experiments, a single i.t. application of four different concentrations of 20:4-NAPE (0.2 µM, 2 µM, 20 µM, and 200 µM) corresponding to the dose of 2 ng, 20 ng, 0.2 µg, and 2 µg per animal in a volume of 10 µl followed by 35 µl of saline was made in combination with in vivo measurement of PWT and PWL before and 1 h, 2 h, and 4 h after i.t. treatment. Rats received i.t. 20:4-NAPE from the lowest to highest concentration, and a two-day interval was maintained between the individual experiments.
In the second series of in vivo experiments, individual animals were tested for the baseline setting. Rats underwent behavioral testing 1 h after i.t. pretreatment with LEI-401 (10 µM, equal to the dose of 42 ng per animal) in the volume of 10 µl followed by 35 µl of saline. Subsequently, i.t. co-administration of LEI-401 (10 µM, 10 µl) and 20:4-NAPE (20 µM or 200 µM, 10 µl) followed by 35 µl of saline was performed, with substances separated by a bubble within one syringe. Behavioral measurement followed 1 h, 2 h, and 4 h after the second i.t. administration. The average values from the hind paws of individual animals were averaged in the experimental groups.
Intrathecal catheter implantation
Similar to our previous works29–31, intrathecal catheters were implanted between the L3 and L4 vertebrae. Polyethylene tubing PE-5 and PE-10 were connected and glued together to be accessible for the drug administration. The catheter implantation was performed under deep anesthesia of 3% isoflurane. Through a longitudinal incision on top of lumbar L3 and L4 the upper lumbar vertebrae were exposed. The L3 vertebra was gently lifted, and the PE-5 catheter end, filled with saline, was placed into the subarachnoid space and fixed to the spine with super glue. The other catheter end was exposed on head and heat-sealed. The animals were observed for neurological deficits after the catheter implantation. None of the animals used in the experiments showed any neurological deficits. Animals were left to recover in their cages for at least 5 days before testing. The position of the catheters was verified visually by a dye injection at the end of each experiment.
Statistical analysis
Data are expressed as mean ± SEM, most of which were normalized to the control/baseline value. Statistical analysis was calculated using GraphPad Prism 10 software. For statistical comparisons, the nonparametric tests (Friedman, Kruskal-Wallis) were used for data sets with control without deviation. The t-test, one-way ANOVA, and repeated measures (RM) one-way ANOVA were used for data analysis with normal distribution. P-value < 0.05 was considered statistically significant.
Materials
All chemicals used for extracellular solutions were of analytical grade and were purchased from Sigma Aldrich (St. Louis, MO, USA) and Tocris Bioscience (Bristol, UK). Anandamide and 20:4-NAPE (Avanti Polar Lipids, Alabaster, AL, USA), LEI-401 (Cayman Chemical, Ann Arbor, MI, USA), PF514273, SB366791 and capsaicin (Tocris Bioscience) were dissolved in DMSO, which always had a concentration of < 0.1% in the final solution.
Results
In vivo, intrathecal administration of 20:4-NAPE induced mechanical analgesia and allodynia depending on the concentration
The impact of i.t. administration of 20:4-NAPE on mechanical sensitivity was examined in rats in vivo. Four concentrations, ranging from 0.2 µM to 200 µM, were evaluated in behavioral experiments testing mechanical threshold. The paw withdrawal threshold (PWT) was not altered by the administration of 0.2 µM (n = 6) or 2 µM 20:4-NAPE (n = 8) between 1 h and 4 h after the i.t. injection (Fig. 1A). Higher concentration of 20:4-NAPE (20 µM) significantly increased the withdrawal threshold 1 h (n = 8, p < 0.01) and 2 h (p < 0.05) after injection, suggesting analgesic effect. The PWT returned to the baseline value 4 h after the treatment. In contrast, further increase in the 20:4-NAPE concentration to 200 µM decreased PWT at 1 h (n = 12, p < 0.01) and 2 h (p < 0.05) after the injection, implying the presence of allodynia. These results indicate that increased levels of 20:4-NAPE may have opposite effects on pain sensitivity, based on the concentration.
To determine whether the production of AEA by NAPE-PLD enzymatic activity is involved in the observed 20:4-NAPE-mediated in vivo effects, the pretreatment with the NAPE-PLD inhibitor, LEI-401 (10 µM, i.t.), was evaluated. When NAPE-PLD inhibitor was applied alone, it did not affect the PWT 1 h after the injection (Baseline: 66.8 ± 1.5 g, LEI-401: 66.5 ± 1.3 g, n = 5). Subsequent co-administration of LEI-401 followed by 20:4-NAPE (20 µM, i.t.) did not alter the PWT (Fig. 1B). Thus, the antinociceptive effect of 20 µM 20:4-NAPE was prevented by LEI-401 pretreatment. In the second experiment the LEI-401 pretreatment alone also did not affect the PWT 1 h after the administration (Baseline: 77.8 ± 4.3 g, LEI-401: 76.7 ± 2.4 g, n = 4). Subsequent co-administration of LEI-401 followed by 20:4-NAPE (200 µM, i.t.) did not change the PWT (Fig. 1C). The allodynia induced by 200 µM 20:4-NAPE was completely blocked by LEI-401 pretreatment. Thus both antinociceptive and pronociceptive effects elicited by the 20:4-NAPE i.t. administration were dependent on NAPE-PLD activation.
Concentration-dependent effect of 20:4-NAPE application on DRG neuron excitability
The impact of 20:4-NAPE on the excitability of primary sensory neurons was investigated in rat DRG cultures. Nociceptive DRG neurons were repeatedly stimulated with a high concentration of KCl (30 mM) every 2 min, and changes in intracellular Ca2+ concentration were measured according to the experimental protocol (see Methods). The control Ca2+ transient amplitude was averaged from the 1st and 2nd K+-induced responses just before the drug application and was set to 0%. The inhibition of the K+-induced Ca2+ transients amplitude was then calculated as a percentage of the control stimulations and presented as positive values in individual graphs. During the repeated excitation of the DRG neurons under the control conditions, the amplitude of the Ca2+ transients showed a small but significant reduction. The inhibition of the K+-evoked response at the 2nd min was 2.0 ± 0.53% (p < 0.001), at the 4th min 4.5 ± 0.79% (p < 0.001) and at the 6th min of the experiment 5.6 ± 0.79% (p < 0.001, Fig. 2A,B). A potent TRPV1 agonist capsaicin was applied at the end of this control experiment. All 211 neurons were tested with capsaicin (0.5 µM, 3 s), and the Ca²⁺ response was elicited in 181 of these neurons, representing 86% of the total. This confirmed that our study was conducted preferentially on the population of nociceptive DRG neurons due to the 40 μm strainer application during the culture preparation, and the vast majority of them expressed functional TRPV1 and responded to the capsaicin application with Ca2+ transient.
Based on this experimental protocol, the effect of four different concentrations of 20:4-NAPE (10 nM, 100 nM, 1 µM, and 10 µM) on the excitability of DRG neurons was tested in separate experiments. Application of 20:4-NAPE (6 min) at lower concentrations significantly inhibited the K+ response at the 2nd min of the application (10 nM, p < 0.001; 100 nM, p < 0.001; and 1 µM, p < 0.001), at the 4th min (10 nM, p < 0.001; 100 nM, p < 0.001; 1 µM, p < 0.001), and at the 6th min (10 nM, p < 0.001; 100 nM, p < 0.001; 1 µM, p < 0.001). In contrast, the application of the highest 10 µM concentration of 20:4-NAPE significantly enhanced K+ response in the 2nd min (p < 0.001) and the 4th min (p < 0.001). At the end (6th min) of the 20:4-NAPE application, the response returned close to the control level present before the 20:4-NAPE treatment (Fig. 2A, B).
Compared to the control situation at the respective times of the application, lower concentrations of 20:4-NAPE significantly inhibited the K+ response. This effect was observed at 10 nM, 100 nM, and 1 µM concentrations, with a stronger inhibition observed during 100 nM 20:4-NAPE application. In comparison, the higher 10 µM concentration of 20:4-NAPE significantly potentiated the K+-evoked Ca2+ transients (Fig. 2B, C). Application of 20:4-NAPE produced concentration-dependent effects on nociceptive DRG neurons. At lower concentrations, 20:4-NAPE decreased the excitability of DRG neurons. Conversely, the high concentration of 20:4-NAPE (10 µM) had the opposite effect.
Concentration-dependent effect of Anandamide application on DRG neuron excitability
Analogous to the experiments with 20:4-NAPE, we examined the impact of direct application of AEA on the excitability of DRG neurons. In order to ascertain the effects of different AEA concentrations, separate experiments were conducted at three lower concentrations within the nM range (1 nM, 10 nM, and 100 nM; 6 min). AEA in higher concentrations has been demonstrated to excite DRG neurons directly32,33, and therefore, the effects of 10 µM AEA were tested separately (see Fig. 6). AEA at a concentration of 1 nM significantly increased the inhibition of the K+-induced response at the 2nd min of the application (p < 0.001), with the level of this inhibition remaining unchanged until the end of the AEA application (p < 0.001 at the 4th and 6th min; Fig. 3A,B). The inhibitory effect of 10 nM AEA (p < 0.001) was comparable to that of 1 nM AEA at the 2nd min of the application. However, this effect was further significantly enhanced at the 4th min of the application (p < 0.001) and persisted until the end of the application at the 6th min (p < 0.001). AEA at the concentration of 100 nM did not elicit the inhibition of the K+-induced Ca2+ response at the 2nd min of the application. Nevertheless, a slight inhibition was observed at the 4th min (p < 0.001), and the level remained similar until the end of the application (p < 0.001 at the 6th min).
The lowest 1 nM AEA concentration significantly inhibited the K+-evoked response compared to the control inhibition of K+ responses at the 2nd and 4th min of the application. The tenfold higher 10 nM AEA concentration elicited the most pronounced inhibition during the whole AEA application. The response of a hundredfold higher 100 nM AEA concentration did not differ from the control K+ response during the whole AEA application (Fig. 3B,C).
The application of the exogenous AEA resulted in a concentration-dependent inhibition (1 nM and 10 nM) of the excitability of nociceptive DRG neurons, with the greatest effect observed at 10 nM. However, the further elevation of the AEA concentration to 100 nM did not affect the excitability of DRG neurons induced by potassium ions.
Blocking NAPE-PLD prevents the 20:4-NAPE-induced inhibition/excitation but does not affect AEA effects
A key enzyme involved in AEA synthesis, NAPE-PLD, is expressed in DRG neurons34. In our experiments, we tested whether NAPE-PLD mediates AEA production from 20:4-NAPE to subsequently induce the inhibitory and excitatory effects on DRG neuron excitability. Incubation of cells (2 h) with subsequent acute application of LEI-401 (1 µM), a NAPE-PLD inhibitor, slightly increased the inhibition of the K+ response in DRG neurons (Fig. 4A) compared to the control experiment without NAPE-PLD inhibition. Although LEI-401 treatment itself had an effect, it also prevented the inhibitory effect of 100 nM 20:4-NAPE application (Fig. 4B) and the excitatory effect of 10 µM 20:4-NAPE application (Fig. 4C). In contrast to 20:4-NAPE, the inhibitory effect of 10 nM AEA application was not prevented by LEI-401 treatment. However, co-application of LEI-401 with 10 nM AEA did not prevent but increased the inhibitory effect compared to AEA applied alone (Fig. 4D). This enhancement of the excitability inhibition may reflect the sub-additive effect of LEI-401 and 10 nM AEA. These results suggest that the production of AEA from 20:4-NAPE via NAPE-PLD likely mediated both the inhibitory and excitatory effects on the excitability of DRG neurons.
CB1 and TRPV1 receptor-mediated mechanisms of action of 20:4-NAPE and AEA
In order to investigate the mechanism underlying the effects mediated by the application of 20:4-NAPE and exogenous AEA, the main AEA target receptors CB1 and TRPV1 were blocked by the antagonists PF514273 or SB366791, respectively.
Activation of the CB1 receptor mediated the inhibitory effects of 20:4-NAPE and AEA application
The following three experiments investigated the role of the CB1 receptor activation in the effects evoked by the application of 20:4-NAPE and AEA. First, the impact of the CB1 receptor inhibition on the inhibitory effect of 100 nM 20:4-NAPE was tested. Before the experiment, the CB1 receptor antagonist PF514273 was applied alone. The inhibition of the K+ response elicited by PF514273 (400 nM, n = 174, 2nd min: 3.3 ± 1.1, 4th min: 5.2 ± 1.1, 6th min: 7.0 ± 1.2) was not significantly different from the control (Fig. 2B). This indicates that CB1 receptor inhibition did not alter the K+ induced excitability of DRG neurons. Pretreatment with CB1 receptor antagonist PF514273 (400 nM, 4 min) and subsequent co-application of PF514273 with 20:4-NAPE (100 nM, 6 min) prevented the inhibitory effect of 100 nM 20:4-NAPE (Fig. 5A). This suggests that the inhibitory effect of 20:4-NAPE on DRG neuron excitability was mediated by CB1 receptor activation.
Second, the effect of the CB1 receptor inhibition on the excitatory effect induced by 10 µM 20:4-NAPE was assessed. Pretreatment with PF514273 (400 nM, 4 min) followed by co-application of PF514273 with 20:4-NAPE (10 µM, 6 min) had a time-dependent effect on DRG excitability. At the 2nd min of co-application, the excitatory effect of 20:4-NAPE was significantly higher compared to the situation without the CB1 antagonist. At the 4th min, the excitatory effect of 20:4-NAPE was not affected, and at the 6th min of co-application, the effect of 20:4-NAPE switched to inhibitory (Fig. 5B). When the CB1 receptors were blocked, the excitatory effect of 20:4-NAPE was increased, probably due to reduced inhibition mediated by CB1 receptors activated by the endogenously produced AEA from 20:4-NAPE. However, this effect was time-dependent, which may reflect TRPV1 receptors desensitization or the decrease in AEA concentration needed to activate TRPV1 receptors.
Third, the role of CB1 antagonist was tested on the inhibitory effect of low concentration of exogenous AEA (10 nM). Pretreatment with PF514273 (400 nM, 4 min) followed by co-application of PF514273 with AEA (10 nM, 6 min) prevented the inhibitory effect of AEA on the DRG excitability (Fig. 5C). Consequently, the inhibitory effect of AEA was mediated by CB1 receptor activation.
Activation of the TRPV1 receptors mediated the excitatory effect of 20:4-NAPE
First, the effect of the TRPV1 antagonist SB366791 was tested alone. The Ca2+ transients induced by the K+ with the SB366791 present (1 µM, n = 103) were different from the control (Fig. 2B) only at the 2nd min (6.0% ± 1.4, p < 0.01, 4th min: 4.2% ± 1.6, 6th min: 7.0% ± 1.4). This indicates that TRPV1 receptors do not play an important role in this type of DRG neurons activation under the control conditions.
The importance of the TRPV1 activation in the effects evoked by the application of 20:4-NAPE and AEA was evaluated in three experiments. Pretreatment with the TRPV1 antagonist SB366791 (1 µM, 4 min) and subsequent co-application of SB366791 with 20:4-NAPE (100 nM, 6 min) did not alter the inhibitory effect of 100 nM 20:4-NAPE when applied alone (Fig. 5D). The mechanism of 20:4-NAPE-induced inhibition did not involve the activation of TRPV1.
Second, the impact of TRPV1 antagonist on the excitatory effect induced by 10 µM 20:4-NAPE was evaluated. Pretreatment with SB366791 (1 µM, 4 min) followed by co-application of SB366791 with 20:4-NAPE (10 µM, 6 min) prevented the excitatory effect of 10 µM 20:4-NAPE on DRG neurons throughout the entire period of 20:4-NAPE application (Fig. 5E) and induced robust inhibition.
Third, the role of TRPV1 activation on the inhibitory effect of exogenously added AEA (10 nM) was investigated. Pretreatment with SB366791 (1 µM, 4 min) followed by co-application of SB366791 with AEA (10 nM, 6 min) did not prevent the inhibitory effect of 10 nM AEA application. Furthermore, the AEA-induced inhibition of K+ responses in DRG neurons increased significantly (Fig. 5F). This indicates that the inhibition of TRPV1 enhanced the CB1 receptor activation-mediated inhibitory effect of AEA.
Application of high concentration of AEA induced Ca2+ transients via TRPV1 activation in DRG neurons
Higher concentrations of AEA are known to induce Ca2+ transients in DRG neurons32,33. Therefore, we investigated the underlying mechanism of AEA-induced excitation of DRG neurons by repeated application of high AEA concentration, on which antagonists of CB1 and TRPV1 receptors were tested.
Anandamide (10 µM, 2 s, 2-min interval) was applied five times, while KCl (30 mM, 2 s) was used to test the excitability of neurons before and after the AEA application. At the end of the protocol, capsaicin (0.5 µM, 3 s) was also applied to identify cells expressing TRPV1 (Fig. 6A). Five consecutive applications of AEA evoked Ca2+ transients of similar amplitude (Fig. 6B). The CB1 antagonist was tested in different experiments, where the acute application of PF514273 (400 nM, 6 min) did not alter the amplitude of Ca2+ responses elicited by brief AEA applications (Fig. 6C,D). In another set of experiments, the TRPV1 antagonist SB36791 was tested in the same fashion. Application of SB36791 (1 µM, 6 min) significantly decreased the Ca2+ response amplitude elicited by AEA application (Fig. 6E,F). These results demonstrate that the increase in intracellular Ca2+ induced by 10 µM AEA application in nociceptive DRG neurons involved activation of TRPV1 but not CB1 receptors.
Discussion
Our study is the first in vivo evaluation of the analgesic effect of intrathecal administration of 20:4-NAPE. The lower concentration of 20:4-NAPE (20 µM) elicited hyposensitivity to mechanical stimuli, whereas the higher concentration (200 µM) caused mechanical allodynia. Both in vivo effects were dependent on NAPE-PLD activity, suggesting that local AEA production from 20:4-NAPE is involved in the modulation of tactile sensitivity.
Alterations in the excitability of DRG neurons contribute to hypersensitive states such as allodynia and hyperalgesia and to spontaneous pain that may occur in chronic pain conditions. In our work, analogous to the impact on tactile sensitivity in vivo, 20:4-NAPE modulated the excitability of DRG neurons in vitro. Application of 20:4-NAPE elicited the concentration-dependent effect on the excitability of nociceptive DRG neurons. The excitability was decreased by the lower concentrations of 20:4-NAPE (from 10 nM to 1 µM) and increased by the application of the high concentration (10 µM). Both excitatory and inhibitory modulatory effects of 20:4-NAPE were prevented by NAPE-PLD antagonist (LEI-401), suggesting that enzymatic activity of NAPE-PLD present in DRG culture was needed. These results also imply that CB1 and TRPV1 receptors are activated after 20:4-NAPE application due to endogenous AEA production and their direct activation by 20:4-NAPE is unlikely. Externally added AEA had a similar impact on DRG neuron excitability. Lower concentrations of AEA (from 1 nM to 10 nM) decreased the K+-induced neuronal excitation, whereas high concentration of AEA (10 µM) produced excitation similar to that evoked by the K+ solution. Inhibition of the CB1 receptor by PF514273 prevented the 20:4-NAPE- or AEA-induced decrease in excitability, whereas TRPV1 inhibition by SB366791 prevented the increase in DRG neuron excitability.
Antinociceptive effect of spinal 20:4-NAPE administration converted to allodynia at high concentration
The AEA-induced analgesia was recognized to be underlined by a peripheral mechanism via CB1 receptor activation in the animal model of neuropathic pain, while increased AEA levels were achieved with a peripherally restricted FAAH inhibitor (URB937)2. In comparison, AEA-induced analgesia mediated by spinal mechanisms has been shown to alleviate neuropathic or inflammatory pain when administered intrathecally. Both CB1 and TRPV1 receptors have been implicated in the underlying mechanisms35–38. In our experiments, we demonstrated in naïve animals that the intrathecal treatment with 20:4-NAPE elicited a dose-dependent effect via NAPE-PLD activation, as lower concentrations induced antinociceptive and high exerted the pro-nociceptive effects. These in vivo effects are consistent with those observed in nociceptive DRG neurons, while we did not report increased activation after 20:4-NAPE application in spinal cord slices18. Presynaptic CB1 and TRPV1 receptor activation is likely to be involved in the underlying mechanism. Compared to the situation in DRG neuronal cultures, the production of AEA from 20:4-NAPE could also be mediated in other cell types, such as glial cells, due to the presence of NAPE-PLD34,39. Our experiments strongly suggest that the dosage of 20:4-NAPE should be carefully determined to achieve analgesia. Excessive production of AEA by NAPE-PLD in the spinal cord may lead to unfavorable pro-nociceptive effects. Altered expression of endocannabinoidome components, including AEA synthesizing and degrading enzymes and target receptors induced by pathological pain conditions, should also be considered in any possible pain treatment application9,40. Previous evidence indicates that peripheral inflammation may induce a switch of the mechanism underlying the inhibition of spinal excitatory synaptic transmission at first nociceptive synapses evoked by 20:4-NAPE application from the CB1 dependent one to both CB1/TRPV1 mediated18,19. The potential use of AEA-modulating drugs for pain treatment may be quite complex. Specific changes in the endocannabinoidome homeostasis in various pathological pain states may alter the mechanisms of endocannabinoid-mediated analgesia, which remains incompletely understood.
20:4-NAPE induced modulation of nociceptive signaling in the spinal cord
In our previous experiments using spinal cord slices, we have suggested that 20:4-NAPE may be better suited for analgesic purposes, compared to AEA application, due to its consistent inhibitory effects on nociceptive synaptic transmission at the first nociceptive synapses in the spinal cord dorsal horn17–19. The hypothesis is that local production of AEA from NAPE, leading to microdomain concentration gradients and activation of surrounding receptors, would be more efficient and have different effects compared to flooding the preparation with exogenous AEA. The presynaptic side of these dorsal horn synapses is formed by central endings of DRG neurons, and neurotransmitter release may be regulated by CB1 and TRPV1 receptors co-expressed on these DRG neurons. However, our in vivo experiments in this work demonstrated that while intrathecal application of low concentration of 20:4-NAPE had strong analgesic effect, the high concentration was pro-nociceptive. This corresponds to previous findings with direct AEA application. AEA at low concentrations inhibited potassium- and capsaicin-evoked release of pronociceptive calcitonin gene-related peptide (CGRP) in the spinal cord dorsal horn35, but at high concentrations, AEA directly evoked release of CGRP and substance P33. These actions parallel activation of CB1 receptors leading to decreased transmitter release and activation of TRPV1 channels, increased Ca2+ influx and enhanced glutamate release13–15. Activation of TRPV1 receptors with high capsaicin concentration, elicited action potentials (APs) in superficial dorsal horn neurons, even while preventing evoked glutamate release by the dorsal root stimulation13,41. In this process, a down-regulation of voltage-activated Ca2+ channels (VACCs) by dephosphorylation via calcineurin following TRPV1 activation may play a role42. In addition, using a voltage-sensitive dye, it has been shown that TRPV1 activation also reduced the presynaptic excitation evoked by dorsal root stimulation of nociceptive fibers43. Notably, electrical stimulation of solitary tract afferents revealed that asynchronous glutamate release triggered long-lasting AP firing on the postsynaptic neuron, and this ability was mediated by TRPV144. Taken together, TRPV1-mediated facilitation of nociceptive transmission in the spinal cord dorsal horn likely contributes to enhanced pain signaling, while robust TRPV1 activation prevent excessive nociceptive transmission.
Impact of 20:4-NAPE on the excitability of DRG neurons
The pseudo-unipolar DRG neurons express CB1 and TRPV1 receptors on both the proximal and distal axonal process, that form the presynaptic ending in the spinal cord and the peripheral nerve ending in the periphery45,46. While the DRG neurons in acute cell culture usually lack these processes, they are used to study the function of receptors expressed in these endings in vivo. In the present study, we have used cultured DRG neurons to further investigate the 20:4-NAPE-mediated modulation of DRG neurons excitation. Both 20:4-NAPE- and externally added AEA at lower concentrations inhibited the excitability of DRG neurons via CB1 receptor activation, whereas higher concentrations increased it via TRPV1 activation. Our findings are consistent with previous reports of AEA-induced effects in DRG neurons. AEA at low concentrations activated the CB1 receptors in DRG neurons to inhibit Ca2+ transients induced by electrical field stimulation33, and to decrease the calcitonin gene-related peptide (CGRP) release in DRG culture47. On the other hand, the high concentrations of AEA induced Ca2+ transients, potentiated CGRP release and increased spontaneous action potentials generation via the TRPV1 activation33,47–49. In comparison, Evans et al. (2004) showed that a single concentration of AEA (1 µM) induced a dual effect on the potassium-induced Ca2+-mediated response, with the observed decrease or increase in excitability being segregated by DRG neuron body size. In these experiments, the inhibitory effect depended on the activation of the Gi/o protein pathway, which is also involved in the signaling downstream of CB1 receptor activation50. Taken together, previous studies and our current results thus strongly support the evidence for a concentration-dependent and CB1- or TRPV1-mediated effect of AEA on nociceptive DRG neurons. However, the AEA-induced effect may also be body size dependent, pointing to the heterogeneity of DRG neurons with differential expression of CB1 and TRPV1 receptors that adds complexity to the effect induced by AEA10,51. In our experiments, we studied a population of small diameter neurons (< 40 μm), majority of which showed responses to TRPV1 receptors activation by capsaicin. Thus, the local concentration of AEA produced from 20:4-NAPE and the exclusive expression or spatial distribution of CB1/TRPV1 receptors52 in the subpopulations of DRG neurons are the essential factors that delineate the effect of endocannabinoids on the excitability of DRG neurons.
While the application of high concentrations of both 20:4-NAPE and AEA induced excitation, there were some differences. Application of 20:4-NAPE did not change the baseline Ca2+ level and potentiated the K+-induced Ca2+ transients. However, this potentiation was clearly reduced at the end of the 6 min application time, probably due to desensitization of TRPV1 receptors. Although we cannot also exclude the possibility that the AEA production/concentration was declining with time, it is unlikely as no change at this time period was observed when lower concentrations of 20:4-NAPE were applied. In addition, the excitatory effect of the high concentration of 20:4-NAPE was enhanced during the first K+-induced depolarization when CB1 receptors were blocked. This suggests that endogenously produced AEA concomitantly activates both CB1 and TRPV1 receptors. Application of high concentration of AEA evoked robust Ca2+ transients and therefore could not be tested with the K+-induced depolarization protocol. These AEA-induced transients did not change their amplitude with repeated application, were not modulated by CB1 antagonist application, but were significantly reduced when TRPV1 receptors activation was blocked. These differences suggest that activation of CB1 and TRPV1 receptors by 20:4-NAPE and AEA may not be equal and may have different consequences on DRG neuron excitability.
When the NAPE-PLD inhibitor LEI-40153 was added alone, in our experiments, the K⁺-induced calcium transients in DRG neurons were slightly suppressed compared to the control conditions. NAPE-PLD is a Ca²⁺-dependent enzyme, so its basal activity under control conditions is likely low. However, the influence of different factors present in the culture media on its activity or some unspecific effects of LEI-401 cannot be excluded. Inhibition of NAPE-PLD may alter the composition of NAPEs in membranes as well as endogenous lipid signaling, including activation of alternative enzymatic pathways. This metabolic imbalance may become more pronounced when DRG neurons are stimulated and accumulate Ca²⁺ ions. The alteration in membrane phospholipids and bioactive lipids composition may potentially affect neuronal excitability also indirectly by modulation of membrane properties, such as membrane fluidity, curvature, and lipid raft organization, and modulate function of ion channels critical for DRG neuron excitability.
Previous studies have demonstrated that a number of endogenous lipids may activate TRPV1 and CB1 receptors9,54. In our earlier experiments, we found that increased concentrations of 20:4-NAPE lead to increased levels of AEA in spinal cord slices18. In the recent study, we have demonstrated that the effects of 20:4-NAPE were dependent on NAPE-PLD activation, further supporting the role of endogenous AEA production via this calcium-sensitive enzyme. Increased activity in DRG neurons leads to increased AEA production, driven by elevated intracellular Ca2+ levels48. Our results show that the concentration of produced AEA can subsequently have complex effects based on the activation of both CB1 and TRPV1 receptors. DRG neurons also express AEA-synthesizing enzymes that are calcium-independent but can be activated by protein kinases23,24. At the same time, activation of protein kinases is critical for TRPV1 sensitization and has been implicated in different pathological pain conditions15,31,55,56. The role of individual AEA synthesizing enzymes in DRG neurons and their importance for pain modulation in normal and pathological conditions needs further investigation.
Funding
This work was supported by the Grant Agency of the Czech Republic 21–02371 S, National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) - Funded by the European Union – Next Generation EU and the Institutional support RVO67985823.
Data availability
The experimental data are available from the corresponding author on reasonable request.
Declarations
Competing interests
The authors declare no competing interests.
Ethics approval
All experiments were approved by the local Institutional Animal Care and Use Committee of IPHYS (Project No 44-2022-P) and were carried out in accordance with the EU Directive 2010/63/EU for animal experiments, the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals, and guidelines of the International Association for the Study of Pain.